✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Pexidartinib hydrochlorideis the generic ingredient in one branded drug marketed by Daiichi Sankyo Inc and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Pexidartinib hydrochloride has one hundred and twenty-five patent family members in forty-one countries.
One supplier is listed for this compound.
Recent Clinical Trials for pexidartinib hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
|Daiichi Sankyo Co., Ltd.||Phase 2|
|Daiichi Sankyo, Inc.||Phase 4|
|Daiichi Sankyo Co., Ltd.||Phase 3|
|Country||Patent Number||Title||Estimated Expiration|
|European Patent Office||2086972||COMPOSÉS MODULANT L'ACTIVITÉ DE C-FMS ET/OU DE C-KIT ET UTILISATIONS ASSOCIÉES (COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR)||See Plans and Pricing|
|New Zealand||577011||COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR||See Plans and Pricing|
|Japan||2020528884||キナーゼを調節する化合物の製剤||See Plans and Pricing|
|European Patent Office||3757104||FORMES SOLIDES D'UN COMPOSÉ MODULANT LES KINASES (SOLID FORMS OF A COMPOUND MODULATING KINASES)||See Plans and Pricing|
|Hong Kong||1248675||調節激酶的1H 吡咯並[2，3-B]吡啶衍生物的合成 (SYNTHESIS OF 1 H-PYRROLO[2,3-B]PYRIDIN DERIVATIVES THAT MODULATE KINASES)||See Plans and Pricing|
|Spain||2447779||See Plans and Pricing|
|China||101605787||Compounds modulating c-fms and/or c-kit activity and uses therefor||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|